顕性肝性脳症 - 市場考察、疫学、市場予測（2034年）

当レポートでは、顕性肝性脳症の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 顕性肝性脳症のエグゼクティブサマリー

第3章 顕性肝性脳症の競合情報分析

第4章 顕性肝性脳症：市場の概要

• 顕性肝性脳症の総市場シェアの分布（2020年）
• 顕性肝性脳症の総市場シェアの分布（2034年）

第5章 顕性肝性脳症：疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病態生理学
• 危険因子
• 診断

第6章 ペイシェントジャーニー

第7章 顕性肝性脳症の疫学と患者人口

• 疫学の主な調査結果
• 前提条件と根拠：主要7市場
• 疫学シナリオ：主要7市場
  • 主要7市場の顕性肝性脳症の疫学シナリオ（2020年～2034年）
• 米国の疫学
  • 米国の顕性肝性脳症の疫学シナリオ（2020年～2034年）
• 欧州5ヶ国の疫学：国別
  • ドイツの疫学
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学
  • 日本の疫学

第8章 治療アルゴリズム、現在の治療、医療行為

• 顕性肝性脳症の治療と管理
• 顕性肝性脳症の治療アルゴリズム

第9章 アンメットニーズ

第10章 顕性肝性脳症治療の主要評価項目

第11章 上市済みの製品

第12章 新治療法

第13章 顕性肝性脳症：主要7市場の分析

• 主な調査結果
• 主要7市場の顕性肝性脳症の市場規模
• 主要7市場の顕性肝性脳症の市場規模：治療法別

第14章 属性分析

第15章 主要7市場：市場見通し

• 米国：市場規模
  • 米国の顕性肝性脳症の総市場規模
  • 米国の顕性肝性脳症の市場規模：治療法別
• 欧州5ヶ国：市場規模と見通し
• ドイツの市場規模
  • ドイツの顕性肝性脳症の総市場規模
  • ドイツの顕性肝性脳症の市場規模：治療法別
• フランスの市場規模
• イタリアの市場規模
• スペインの市場規模
• 英国の市場規模
  • 英国の顕性肝性脳症の総市場規模
  • 英国の顕性肝性脳症の市場規模：治療法別
• 日本市場の見通し
  • 日本の市場規模

第16章 顕性肝性脳症のアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Overt Hepatic Encephalopathy Epidemiology (2020-2034)
• Table 2: 7MM Overt Hepatic Encephalopathy Diagnosed and Treatable Cases (2020-2034)
• Table 3: Overt Hepatic Encephalopathy Epidemiology in the United States (2020-2034)
• Table 4: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Overt Hepatic Encephalopathy Epidemiology in Germany (2020-2034)
• Table 6: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Overt Hepatic Encephalopathy Epidemiology in France (2020-2034)
• Table 8: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Overt Hepatic Encephalopathy Epidemiology in Italy (2020-2034)
• Table 10: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Overt Hepatic Encephalopathy Epidemiology in Spain (2020-2034)
• Table 12: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Overt Hepatic Encephalopathy Epidemiology in the UK (2020-2034)
• Table 14: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Overt Hepatic Encephalopathy Epidemiology in Japan (2020-2034)
• Table 16: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Overt Hepatic Encephalopathy Epidemiology (2020-2034)
• Figure 2: 7MM Overt Hepatic Encephalopathy Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Overt Hepatic Encephalopathy Epidemiology in the United States (2020-2034)
• Figure 4: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Overt Hepatic Encephalopathy Epidemiology in Germany (2020-2034)
• Figure 6: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Overt Hepatic Encephalopathy Epidemiology in France (2020-2034)
• Figure 8: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Overt Hepatic Encephalopathy Epidemiology in Italy (2020-2034)
• Figure 10: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Overt Hepatic Encephalopathy Epidemiology in Spain (2020-2034)
• Figure 12: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Overt Hepatic Encephalopathy Epidemiology in the UK (2020-2034)
• Figure 14: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Overt Hepatic Encephalopathy Epidemiology in Japan (2020-2034)
• Figure 16: Overt Hepatic Encephalopathy Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Overt Hepatic Encephalopathy - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Overt Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Overt Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Overt Hepatic Encephalopathy market report provides current treatment practices, emerging drugs, Overt Hepatic Encephalopathy market share of the individual therapies, current and forecasted Overt Hepatic Encephalopathy market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Overt Hepatic Encephalopathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Overt Hepatic Encephalopathy Disease Understanding and Treatment Algorithm

The DelveInsight Overt Hepatic Encephalopathy market report gives a thorough understanding of the Overt Hepatic Encephalopathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Overt Hepatic Encephalopathy.

Treatment

It covers the details of conventional and current medical therapies available in the Overt Hepatic Encephalopathy market for the treatment of the condition. It also provides Overt Hepatic Encephalopathy treatment algorithms and guidelines in the United States, Europe, and Japan.

Overt Hepatic Encephalopathy Epidemiology

The Overt Hepatic Encephalopathy epidemiology division provide insights about historical and current Overt Hepatic Encephalopathy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Overt Hepatic Encephalopathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Overt Hepatic Encephalopathy Epidemiology

The epidemiology segment also provides the Overt Hepatic Encephalopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Overt Hepatic Encephalopathy Drug Chapters

Drug chapter segment of the Overt Hepatic Encephalopathy report encloses the detailed analysis of Overt Hepatic Encephalopathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Overt Hepatic Encephalopathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Overt Hepatic Encephalopathy treatment.

Overt Hepatic Encephalopathy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Overt Hepatic Encephalopathy treatment.

Overt Hepatic Encephalopathy Market Outlook

The Overt Hepatic Encephalopathy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Overt Hepatic Encephalopathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Overt Hepatic Encephalopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Overt Hepatic Encephalopathy market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Overt Hepatic Encephalopathy market in 7MM.

The United States Market Outlook

This section provides the total Overt Hepatic Encephalopathy market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Overt Hepatic Encephalopathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Overt Hepatic Encephalopathy market size and market size by therapies in Japan is also mentioned.

Overt Hepatic Encephalopathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Overt Hepatic Encephalopathy market or expected to get launched in the market during the study period 2020-2034. The analysis covers Overt Hepatic Encephalopathy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Overt Hepatic Encephalopathy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Overt Hepatic Encephalopathy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Overt Hepatic Encephalopathy emerging therapies.

Reimbursement Scenario in Overt Hepatic Encephalopathy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Overt Hepatic Encephalopathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Overt Hepatic Encephalopathy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Overt Hepatic Encephalopathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Overt Hepatic Encephalopathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Overt Hepatic Encephalopathy epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Overt Hepatic Encephalopathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Overt Hepatic Encephalopathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Overt Hepatic Encephalopathy market

Report Highlights:

• In the coming years, Overt Hepatic Encephalopathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Overt Hepatic Encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Overt Hepatic Encephalopathy. Launch of emerging therapies will significantly impact the Overt Hepatic Encephalopathy market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Overt Hepatic Encephalopathy
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Overt Hepatic Encephalopathy Report Insights

• Patient Population
• Therapeutic Approaches
• Overt Hepatic Encephalopathy Pipeline Analysis
• Overt Hepatic Encephalopathy Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Overt Hepatic Encephalopathy Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Overt Hepatic Encephalopathy Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Overt Hepatic Encephalopathy Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Overt Hepatic Encephalopathy market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Overt Hepatic Encephalopathy total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Overt Hepatic Encephalopathy market size during the forecast period (2024-2034)?
• At what CAGR, the Overt Hepatic Encephalopathy market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Overt Hepatic Encephalopathy market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Overt Hepatic Encephalopathy market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Overt Hepatic Encephalopathy?
• What is the historical Overt Hepatic Encephalopathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Overt Hepatic Encephalopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Overt Hepatic Encephalopathy?
• Out of all 7MM countries, which country would have the highest prevalent population of Overt Hepatic Encephalopathy during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Overt Hepatic Encephalopathy treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Overt Hepatic Encephalopathy in the USA, Europe, and Japan?
• What are the Overt Hepatic Encephalopathy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Overt Hepatic Encephalopathy?
• How many therapies are developed by each company for Overt Hepatic Encephalopathy treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Overt Hepatic Encephalopathy treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Overt Hepatic Encephalopathy therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Overt Hepatic Encephalopathy and their status?
• What are the key designations that have been granted for the emerging therapies for Overt Hepatic Encephalopathy?
• What are the global historical and forecasted market of Overt Hepatic Encephalopathy?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Overt Hepatic Encephalopathy market
• To understand the future market competition in the Overt Hepatic Encephalopathy market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Overt Hepatic Encephalopathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Overt Hepatic Encephalopathy market
• To understand the future market competition in the Overt Hepatic Encephalopathy market

Table of Contents

1. Key Insights

2. Executive Summary of Overt Hepatic Encephalopathy

3. Competitive Intelligence Analysis for Overt Hepatic Encephalopathy

4. Overt Hepatic Encephalopathy: Market Overview at a Glance

• 4.1. Overt Hepatic Encephalopathy Total Market Share (%) Distribution in 2020
• 4.2. Overt Hepatic Encephalopathy Total Market Share (%) Distribution in 2034

5. Overt Hepatic Encephalopathy: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Overt Hepatic Encephalopathy Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Overt Hepatic Encephalopathy Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Overt Hepatic Encephalopathy Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Overt Hepatic Encephalopathy Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Overt Hepatic Encephalopathy Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Overt Hepatic Encephalopathy Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Overt Hepatic Encephalopathy Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Overt Hepatic Encephalopathy Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Overt Hepatic Encephalopathy Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Overt Hepatic Encephalopathy Treatment and Management
• 8.2. Overt Hepatic Encephalopathy Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Overt Hepatic Encephalopathy Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Overt Hepatic Encephalopathy: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Overt Hepatic Encephalopathy Market Size in 7MM
• 13.3. Overt Hepatic Encephalopathy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Overt Hepatic Encephalopathy Total Market Size in the United States
  • 15.1.2. Overt Hepatic Encephalopathy Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Overt Hepatic Encephalopathy Total Market Size in Germany
  • 15.3.2. Overt Hepatic Encephalopathy Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Overt Hepatic Encephalopathy Total Market Size in France
  • 15.4.2. Overt Hepatic Encephalopathy Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Overt Hepatic Encephalopathy Total Market Size in Italy
  • 15.5.2. Overt Hepatic Encephalopathy Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Overt Hepatic Encephalopathy Total Market Size in Spain
  • 15.6.2. Overt Hepatic Encephalopathy Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Overt Hepatic Encephalopathy Total Market Size in the United Kingdom
  • 15.7.2. Overt Hepatic Encephalopathy Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Overt Hepatic Encephalopathy Total Market Size in Japan
  • 15.8.3. Overt Hepatic Encephalopathy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Overt Hepatic Encephalopathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.